实用医学杂志Issue(7)：1065-1068,4.DOI:10.3969/j.issn.1006-5725.2015.07.008
基因B／C型HBeAg（＋）慢性乙型肝炎患者初始拉米夫定、阿德福韦酯联合治疗疗效
A randomized study of de novo combination therapy lamivudine plus adefovir in HBeAg-positive chronic hepatitis B patients with genotype B/C
摘要
Abstract
Objective To observe the efficacy of de novo combination therapy lamivudine plus adefovir , lamivudine monotherapy and entecavir monotherapy in HBeAg-positive CHB patients with genotype B/C. Methods A total of 182 treatment-naive CHB patients in line with treatment standards of Chinese CHB prevention and treatment guidelines were randomly assigned to three groups and treated with lamivudine plus adefovir or lamivudine monotherapy or entecavir monotherapy for 48 weeks. Results Patients in three groups presented no difference in baseline levels. After treatment by three therapies , the group of lamivudine plus adefovir showed a higher biochemical response rates (12 week P < 0.01, 24 week P < 0.01, 48 week P < 0.01), HBeAg-serological rates(12 week P < 0.01, 24 week P < 0.05, 48 week P < 0.05) and completely virological response rates (12 week P < 0.05, 24 week P < 0.05, 48 week P < 0.05) than lamivudine group. In terms of biochemical response rates , the group of lamivudine plus adefovir had certain advantages when compared with entecavir group. Conclusion De novo combination therapy lamivudine plus adefovir is a good antiviral strategy for chronic hepatitis B patients with B/C genotype viral infection in China.关键词
肝炎,乙型,慢性/拉米夫定/阿德福韦酯/联合治疗Key words
Hepatitis B , chronic/Lamivudine/Adefovir/Combination therapy引用本文复制引用
刘怀鄂,游晶,陈红英,范晶华,刘华,张茹薏,饶少锋,马思佳..基因B／C型HBeAg（＋）慢性乙型肝炎患者初始拉米夫定、阿德福韦酯联合治疗疗效[J].实用医学杂志,2015,(7):1065-1068,4.基金项目
云南省科技厅应用基础研究面上项目 （）
